Acquisition and Loss of Developmental Milestones and Time to Disease-Related Outcomes in Cerebral Alexander Disease.

IF 2 4区 医学 Q3 CLINICAL NEUROLOGY Journal of Child Neurology Pub Date : 2023-12-01 Epub Date: 2023-11-03 DOI:10.1177/08830738231210040
Joshua Joung, Kathryn Gallison, John Jack Sollee, Nicholas Vigilante, Hannah Cooper, Geraldine W Liu, Lance Ballester, Walter Faig, Amy T Waldman
{"title":"Acquisition and Loss of Developmental Milestones and Time to Disease-Related Outcomes in Cerebral Alexander Disease.","authors":"Joshua Joung, Kathryn Gallison, John Jack Sollee, Nicholas Vigilante, Hannah Cooper, Geraldine W Liu, Lance Ballester, Walter Faig, Amy T Waldman","doi":"10.1177/08830738231210040","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> To determine the ages at acquisition of developmental milestones, loss of motor function, and clinical symptoms in Alexander disease. <b>Methods:</b> Patients with confirmed cerebral Alexander disease were included. Data abstraction of developmental and disease-specific milestones was performed from medical records, physical exams, and questionnaires. Mixed effects logistic regression was used to determine if key clinical features were associated with milestone achievement, controlling for patient age. <b>Results:</b> 51 patients with cerebral/infantile Alexander disease were evaluated at a mean age of 10.96 years (range 2.29-31.08 years). Developmental milestones in Alexander disease were often achieved but delayed. Ambulation was achieved in 44 subjects (86%); 34 (67%) subjects walked independently (mean age 1.9 years, range 0.91-3.25 years) and an additional 10 (20%) subjects walked with assistance (mean age 3.9 years, range 1.8-8 years) but did not progress to independent ambulation. Developmental delay was the earliest and most prevalent symptom (N = 48 [94%], mean age 0.58 years), compared to an initial seizure (N = 41 [80%], mean age 2.80 years), and macrocephaly (N = 28 [55%], mean age 4.04 years), <i>P</i> < .0001 between these ages of onset. Loss of independent ambulation occurred in 11 of the 34 (32%) children who had acquired ambulation (range 3.41-15.10 years). Presence of seizures or macrocephaly did not predict the achievement or loss of ambulation. <b>Conclusions:</b> The clinical triad of developmental delay, seizures, and macrocephaly are not universally present in cerebral Alexander disease. Clinicians should have a high index of suspicion for Alexander disease in patients with mild delays and a first seizure.</p>","PeriodicalId":15319,"journal":{"name":"Journal of Child Neurology","volume":" ","pages":"672-678"},"PeriodicalIF":2.0000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Child Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/08830738231210040","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/3 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To determine the ages at acquisition of developmental milestones, loss of motor function, and clinical symptoms in Alexander disease. Methods: Patients with confirmed cerebral Alexander disease were included. Data abstraction of developmental and disease-specific milestones was performed from medical records, physical exams, and questionnaires. Mixed effects logistic regression was used to determine if key clinical features were associated with milestone achievement, controlling for patient age. Results: 51 patients with cerebral/infantile Alexander disease were evaluated at a mean age of 10.96 years (range 2.29-31.08 years). Developmental milestones in Alexander disease were often achieved but delayed. Ambulation was achieved in 44 subjects (86%); 34 (67%) subjects walked independently (mean age 1.9 years, range 0.91-3.25 years) and an additional 10 (20%) subjects walked with assistance (mean age 3.9 years, range 1.8-8 years) but did not progress to independent ambulation. Developmental delay was the earliest and most prevalent symptom (N = 48 [94%], mean age 0.58 years), compared to an initial seizure (N = 41 [80%], mean age 2.80 years), and macrocephaly (N = 28 [55%], mean age 4.04 years), P < .0001 between these ages of onset. Loss of independent ambulation occurred in 11 of the 34 (32%) children who had acquired ambulation (range 3.41-15.10 years). Presence of seizures or macrocephaly did not predict the achievement or loss of ambulation. Conclusions: The clinical triad of developmental delay, seizures, and macrocephaly are not universally present in cerebral Alexander disease. Clinicians should have a high index of suspicion for Alexander disease in patients with mild delays and a first seizure.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
脑亚历山大病发育里程碑的获得和丧失以及与疾病相关的结果的时间。
目的:确定亚历山大病获得发育里程碑、运动功能丧失和临床症状的年龄。方法:纳入已确诊的脑亚历山大病患者。从医疗记录、体检和问卷中提取发育和疾病特异性里程碑的数据。混合效应逻辑回归用于确定关键临床特征是否与里程碑成就相关,并控制患者年龄。结果:评估了51例大脑/婴儿亚历山大病患者,平均年龄10.96岁(2.29-31.08岁)。亚历山大病的发育里程碑经常实现,但被推迟了。44名受试者(86%)实现了伏击;34名(67%)受试者独立行走(平均年龄1.9岁,范围0.91-3.25岁),另有10名(20%)受试人在辅助下行走(平均岁3.9岁,范围1.8-8岁),但未发展为独立行走。发育迟缓是最早和最普遍的症状(N = 48[94%],平均年龄0.58岁) = 41[80%],平均年龄2.80岁)和小头畸形(N = 28[55%],平均年龄4.04岁),P 结论:发育迟缓、癫痫发作和小头畸形的临床三联征在脑亚历山大病中并不普遍存在。对于轻度延迟和首次癫痫发作的患者,临床医生应该对亚历山大病有很高的怀疑指数。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Child Neurology
Journal of Child Neurology 医学-临床神经学
CiteScore
4.20
自引率
5.30%
发文量
111
审稿时长
3-6 weeks
期刊介绍: The Journal of Child Neurology (JCN) embraces peer-reviewed clinical and investigative studies from a wide-variety of neuroscience disciplines. Focusing on the needs of neurologic patients from birth to age 18 years, JCN covers topics ranging from assessment of new and changing therapies and procedures; diagnosis, evaluation, and management of neurologic, neuropsychiatric, and neurodevelopmental disorders; and pathophysiology of central nervous system diseases.
期刊最新文献
Anti-CD20 Therapy in Children With Severe Epstein-Barr Virus-Associated Meningoencephalitis. First-Drug Efficacy and Drug-Resistant Epilepsy Rates in Children With New-Onset Epilepsies: A Multicenter Large Cohort Study. Hammersmith Neonatal and Infant Neurological Examinations Scores in Typically Developing Infants Aged 1-6 Months. Determination of Health Concepts in β-Propeller Protein-Associated Neurodegeneration. The Initial Experience of Eslicarbazepine in Children at Three Canadian Tertiary Pediatric Care Centers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1